Evidence map›Paper›PMID 38168149›Full record

ArticleScientific reports2024

Modelling bronchial epithelial-fibroblast cross-talk in idiopathic pulmonary fibrosis (IPF) using a human-derived in vitro air liquid interface (ALI) culture.

Sarah L Barron, Owen Wyatt, Andy O'Connor, David Mansfield, E Suzanne Cohen, Tomasz M Witkos, Sam Strickson, Róisín M Owens

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. A practical toolbox for modelling fibrosis in vitro.Nature biomedical engineering · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Pathogenic expansion: fibroblast proliferation fuels fibrosis.The Journal of clinical investigation · 2025
    Article
  7. Dressed in Collagen: 2D and 3D Cardiac Fibrosis Models.International journal of molecular sciences · 2025
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Sarah L BarronChemical Engineering and Biotechnology Department, University of Cambridge, Cambridge, UK. slb222@cam.ac.uk.
Owen WyattResearch and Early Development, Respiratory and Immunology, Bioscience Asthma and Skin Immunity, AstraZeneca, Cambridge, UK.
Andy O'ConnorResearch and Early Development, Respiratory and Immunology, Bioscience Asthma and Skin Immunity, AstraZeneca, Cambridge, UK.
David MansfieldImaging and Data Analytics, Clinical Pharmacology and Safety Sciences, AstraZeneca, Cambridge, UK.
E Suzanne CohenResearch and Early Development, Respiratory and Immunology, Bioscience Asthma and Skin Immunity, AstraZeneca, Cambridge, UK.
Tomasz M WitkosAnalytical Sciences, Bioassay, Biosafety and Impurities, BioPharmaceutical Development, AstraZeneca, Cambridge, UK.
Sam StricksonResearch and Early Development, Respiratory and Immunology, Bioscience Asthma and Skin Immunity, AstraZeneca, Cambridge, UK.
Róisín M OwensChemical Engineering and Biotechnology Department, University of Cambridge, Cambridge, UK. rmo37@cam.ac.uk.
AstraZeneca (United Kingdom) · GBUniversity of Cambridge · GBBioPharm (United Kingdom) · GB

Funding

Engineering and Physical Sciences Research Council Centre for Doctoral Training in Sensor Technologies and Applications EP/L015889/1
6 · The paper itself

Abstract

Idiopathic Pulmonary Fibrosis (IPF) is a devastating form of respiratory disease with a life expectancy of 3-4 years. Inflammation, epithelial injury and myofibroblast proliferation have been implicated in disease initiation and, recently, epithelial-fibroblastic crosstalk has been identified as a central driver. However, the ability to interrogate this crosstalk is limited due to the absence of in vitro models that mimic physiological conditions. To investigate IPF dysregulated cross-talk, primary normal human bronchial epithelial (NHBE) cells and primary normal human lung fibroblasts (NHLF) or diseased human lung fibroblasts (DHLF) from IPF patients, were co-cultured in direct contact at the air-liquid interface (ALI). Intercellular crosstalk was assessed by comparing cellular phenotypes of co-cultures to respective monocultures, through optical, biomolecular and electrical methods. A co-culture-dependent decrease in epithelium thickness, basal cell mRNA (P63, KRT5) and an increase in transepithelial electrical resistance (TEER) was observed. This effect was significantly enhanced in DHLF co-cultures and lead to the induction of epithelial to mesenchymal transition (EMT) and increased mRNA expression of TGFβ-2, ZO-1 and DN12. When stimulated with exogenous TGFβ, NHBE and NHLF monocultures showed a significant upregulation of EMT (COL1A1, FN1, VIM, ASMA) and senescence (P21) markers, respectively. In contrast, direct NHLF/NHBE co-culture indicated a protective role of epithelial-fibroblastic cross-talk against TGFβ-induced EMT, fibroblast-to-myofibroblast transition (FMT) and inflammatory cytokine release (IL-6, IL-8, IL-13, IL-1β, TNF-α). DHLF co-cultures showed no significant phenotypic transition upon stimulation, likely due to the constitutively high expression of TGFβ isoforms prior to any exogenous stimulation. The model developed provides an alternative method to generate IPF-related bronchial epithelial phenotypes in vitro, through the direct co-culture of human lung fibroblasts with NHBEs. These findings highlight the importance of fibroblast TGFβ signaling in EMT but that monocultures give rise to differential responses compared to co-cultures, when exposed to this pro-inflammatory stimulus. This holds implications for any translation conclusions drawn from monoculture studies and is an important step in development of more biomimetic models of IPF. In summary, we believe this in vitro system to study fibroblast-epithelial crosstalk, within the context of IPF, provides a platform which will aid in the identification and validation of novel targets.

Indexed as

Epithelial-Mesenchymal TransitionIdiopathic Pulmonary FibrosisFibroblastsHumansRNA, MessengerTransforming Growth Factor betaRNA, MessengerTransforming Growth Factor beta

Identifiers

PMID38168149
PMCPMC10761879
OpenAlexW4390510962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.